Relative Strength Index (RSI)
|Bid||8.64 x 1100|
|Ask||8.70 x 800|
|Day's Range||7.01 - 8.85|
|52 Week Range||3.33 - 19.60|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The global death toll from the coronavirus that causes COVID-19 climbed above 360,000 on Friday, as Brazil, South Korea, the Philippines, Iran and Portugal all reported spikes in infections.
Stocks pared back losses Friday after President Donald Trump delivered a China-focused speech that was more restrained than expected. There was no talk of sanctions or raised tariffs on Chinese goods.
Per an Australian regulator's decision, Sonoma Pharmaceuticals can label a disinfectant sold in the country as effective against covid-19.
Shares of Sonoma Pharmaceuticals Inc. nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of hypochlorous acid products and partner Dubai-based MicroSafe Group said their Nanocyn disinfectant and sanitizer was entered into the Australian Register of Therapeutic Goods for use against the SARS-CoV-2 virus. Trading volume in Sonoma's stock, which soared 160%, swelled to 1.6 million shares ahead of the open, compared with the full-day average of about 43,000 shares. Nanocyn is manufactured using Sonoma's Microcyn technology. "We have been fighting global pandemics for nearly 20 years with our safe and non-toxic Microcyn based disinfectant and we are very pleased with the test results and subsequent approval of the SARS-CoV-2 (COVID-19) label claim for our Nanocyn disinfectant in Australia," said MicroSafe Chief Executive Safa Qadumi. "The label claim comes with a 30 second virucidal kill time on hard surfaces, a landmark kill time for a non-toxic disinfectant." Sonoma's stock has gained 2.7% over the past three months through Thursday, while the S&P 500 has tacked on 2.6%.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfectant & Sanitizer, which is manufactured by Sonoma using its patented Microcyn® Technology, to be entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19). Claims that a disinfectant has a virucidal effect must be expressly permitted by the Australian Therapeutic Goods Administration before being used in consumer advertising (including on the label) in Australia.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology.
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
Sonoma Pharmaceuticals, Inc. (SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care, disinfection and animal health care products in the Middle East, Australia and Europe for $1.1 million with MicroSafe Group. Sonoma’s long-term partnership with MicroSafe in the Middle East has led to the successful growth of sales of Microcyn® Technology products in the region. Sonoma’s unique and versatile Microcyn® Technology has, for example, been widely used for wound cleansing and irrigation, as well as a disinfectant for surfaces, such as in Mecca during the Hajj season, to reduce the risk of transmission of infectious diseases.
PETALUMA, Calif., Feb. 14, 2020 -- Quarterly Net Loss Reduced by 53% Compared to Prior YearYTD Net Loss Reduced by 82% Compared to Prior YearTotal YTD Revenues of $14.4 Million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...
Sonoma Pharmaceuticals, Inc. (SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it has commenced a process to explore and evaluate strategic alternatives for its U.S. Dermatology Division and has engaged Maxim Group LLC as its financial advisor to assist in this process. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public offering price of $3.50 per share. The net proceeds to Sonoma Pharmaceuticals, Inc. from this offering are approximately $1.4 million after deducting the placement agent commissions and other estimated offering expenses payable by Sonoma. Sonoma Pharmaceuticals, Inc. intends to use the net proceeds from the offering for general working capital, especially to fund marketing and product development efforts.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of its common stock at a public offering price of $3.50 per share, with anticipated gross proceeds of $1.6 million, before deducting placement agent fees and offering expense payable by the Company. Dawson James Securities, Inc. is acting as the lead placement agent and sole book runner. The offering of these securities is being made only by means of a prospectus and a related prospectus supplement, which will be filed with the SEC.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock. Dawson James Securities, Inc. is acting as the lead placement agent and sole book runner. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-221477) previously filed with the Securities and Exchange Commission (“SEC”) and subsequently declared effective on November 27, 2017.
Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical.
This week we saw the Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) share price climb by 12%. But will that heal all the...
Bubba Sandford left Sonoma on September 25 after nine months as CEO and Interim CFO after successfully evaluating the Company’s prospects while substantially reducing its cash burn. Mr. Sandford will remain on the Board of Directors for six months following his departure date. The Board of Directors named Amy Trombly as Sonoma’s Interim Chief Executive Officer and promoted John Dal Poggetto to Chief Financial Officer, effective immediately.
If you want to know who really controls Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), then you'll have to look at the...
Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue46% Increase in Dermatology Revenue23% Reduction in Operating Expenses PETALUMA, Calif., Aug..
Sonoma Pharmaceuticals, Inc. (SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it received a formal determination letter from Nasdaq notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Capital Market® and is no longer subject to delisting at this time. As announced previously, on January 4, 2019, Sonoma received a letter from Nasdaq, indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. Nasdaq granted the company a compliance period of 180 calendar days, or until July 3, 2019, to regain compliance with the listing rule.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 8) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Inspire ...
Strong Annual Year-Over-Year Growth with 14% Revenue Growth Strong Quarter-Over-Quarter Growth with 20% Revenue Growth and 25% Reduction in Expenses Reduction in Annual.
Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (SNOA), today announced the timing for a 1-for-9 reverse split of its outstanding common stock which will be effected on June 19, 2019 at 5:00 pm EDT. Sonoma common stock will begin trading on The Nasdaq Capital Market on a 1-for-9 adjusted basis when the market opens on June 20, 2019. The reverse stock split was previously approved by the Company’s stockholders at the Company’s Special Meeting held on May 30 and June 11, 2019.